|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 东营三角洲演化特征与岩性圈闭分布规律<英文>显示文摘东营三角洲是东营凹陷古近系沙河街组沙三段的主要沉积体系之一,为一大型复合三角洲。该三角训形成的浊积砂体岩性圈闭是东营凹陷沙三段重要的勘探目标,近几年平均每年发现的岩性油藏石油储量超过千万吨。为了给东营三角洲隐蔽油气藏进一步的勘探提供科学依据,运用高分辨率层序地层学理论和分析方法,在建立高频层序地层格架的基础上,研究东营三角洲演化过程、古构造坡折发育类型及不同期次三角洲与构造坡折的配置关系,分析这些因素对岩性圈闭形成的重要作用,认为在进积时期推进距离较远(三角洲进积作用大于加积作用)、退积时期湖泛规模较大条件下发育的三角洲朵叶体易形成具有一定规模的浊积扇。 | 方勇 邓宏文 Massimo SARTI 万晓樵 冯晓杰 | 2003 | 石油勘探与开发2003，30，5： | 5 |
| 2 | Cretaceous oceanic red beds and land ocean interaction显示文摘 | WAN Xiao-qiao Massimo Sarti | 2005 | Cretaceous Research2005，26，1： | 1 |
| 3 | Upper Cretaceous oceanic red beds in southern Tibet: A major change from anoxic to oxic, deep-sea environments 显示文摘 | Chengshan Wang Xiumian Hu Massimo Sarti | 2005 | Cretaceous Research2005，26，： | 1 |
| 4 | Upper Cretaceous oceanic red beds in southern Tibet:a major change from anoxic to oxic,deep-sea environments显示文摘 | Wang C S Hu X M Massimo Sarti | 2005 | Cretaceous Research2005，26，1： | 1 |
| 5 | Upper Cretaceous oceanic red beds in Southern Tibet: A major change from anoxic to oxie, deep-sea environments显示文摘 | Wang C S Hu X M Massimo Sarti | 2005 | Cretaceous Research2005，26，1： | 1 |
| 6 | Highly selective sorting of semiconducting single wall carbon nanotubes exhibiting light emission at telecom wavelengths显示文摘单个墙碳 nanotubes (SWNT ) 以他们的非凡的电子性质著名。然而,大多数合成方法导致把不同 chiralities 与联系了的碳 nanotubes 的混合物的生产金属性(m-SWNTs ) 并且半导体(s-SWNTs ) 特征。为应用程序目的,为分开这些的有效方法种类高度被需要。这里,我们为完成 s-SWNTs 的高度选择的分离报导一个协议展出在 1,550 nm 集中的基本光转变。我们采用帮助的聚合物排序的准备方法的途径,和影响光并且分开的 nanotubes 的运输表演被分析。当甚至 m-SWNTs 的踪迹能极其影响表演,我们试图生产不包含剩余 m-SWNTs 的任何可检测的部分的样品。 | Francesco Sarti Francesco Biccari Federica Fioravanti Ughetta Torrini Anna Vinattieri Vincent Derycke Massimo Gurioli Arianna Filoramo | 2016 | Nano Research2016，9，8： | 1 |
| 7 | 西班牙南部Subbetic中带Río Fardes剖面Turonian-Coniacian大洋红层(英文)显示文摘Río Fardes剖面位于西班牙南部Granada东北,构造上属于深水环境的Subbetic中带。该剖面主要由白垩纪Fardes组第Ⅱ段和第Ⅲ段(半)远洋沉积构成,并出现浊流沉积和混杂沉积。本次研究在Fardes组浊流层序内首次发现两段红色沉积。钙质超微化石表明红层的时间从Turonian早期(UC7 带)到Coniacian中期—晚期界线(UC10/?UC11带)。红层由mm级红色泥岩夹灰色、杂色、偶尔黑色泥岩和钙质泥岩组成。沉积学研究表明新发现的Turonian Coniacian远洋红色泥岩沉积形成于CCD面之下深水盆地环境,浊流和碎屑流沉积强烈地影响着(半)远洋环境的背景泥岩相,并成为红色沉积结束的原因。 | 胡修棉 ■vábenická LILIAN Sarti MASSIMO | 2005 | 地学前缘2005，12，2： | 1 |
| 8 | Hyperthermia combined with chemotherapy vs chemotherapy in patients with advanced pancreatic cancer:A multicenter retrospective observational comparative study显示文摘BACKGROUND Several studies report the useful therapeutic results of regional hyperthermia in association with chemotherapy(CHT) and radiotherapy for the treatment of pancreatic cancer. Modulated electrohyperthermia(mEHT) is a new hyperthermia technique that induces immunogenic death or apoptosis of pancreatic cancer cells in laboratory experiments and increases tumor response rate and survival in pancreatic cancer patients, offering beneficial therapeutic effects against this severe type of cancer.AIM To assess survival, tumor response and toxicity of mEHT alone or combined with CHT compared with CHT for the treatment of locally advanced or metastatic pancreatic cancer.METHODS This was a retrospective data collection on patients affected by locally advanced or metastatic pancreatic cancer(stage Ⅲ and IV) performed in 9 Italian centers, members of International Clinical Hyperthermia Society-Italian Network. This study included 217 patients, 128(59%) of them were treated with CHT(no-mEHT) and 89(41%) patients received mEHT alone or in association with CHT. mEHT treatments were performed applying a power of 60-150 watts for 40-90 min, simultaneously or within 72 h of administration of CHT.RESULTS Median patients’ age was 67 years(range 31-92 years). mEHT group had a median overall survival greater than non-mEHT group(20 mo, range 1.6-24, vs 9 mo, range 0.4-56.25, P < 0.001). mEHT group showed a higher number of partial responses(45% vs 24%, P = 0.0018) and a lower number of progressions(4% vs 31%, P < 0.001) than the no-mEHT group, at the three months follow-up. Adverse events were observed as mild skin burns in 2.6% of mEHT sessions.CONCLUSION mEHT seems safe and has beneficial effects on survival and tumor response of stage Ⅲ-IV pancreatic tumor treatment. Further randomized studies are warranted to confirm or not these results. | Giammaria Fiorentini Donatella Sarti Andrea Mambrini Ivano Hammarberg Ferri Massimo Bonucci Paola Giordano Sciacca Marco Ballerini Salvatore Bonanno Carlo Milandri Roberto Nani Stefano Guadagni Patrizia Dentico Caterina Fiorentini | 2023 | World Journal of Clinical Oncology2023，14，6： | 0 |
| 9 | Locoregional therapy and systemic cetuximab to treat colorectal liver metastases显示文摘AIM: To investigate efficacy and safety of second-line treatment with irinotecan-loaded drug-eluting beads(DEBIRI) and cetuximab(DEBIRITUX) of unresectable colorectal liver metastases.METHODS: Patients with the following characteristics were included in the study: unresectable hepatic metastases from colorectal carcinoma(CRC-LM), progression after first line chemotherapy(any type of chemotherapeutic drug and combination was allowed), second line treatment(mandatory), which included for each patient(unregarding the KRas status) two cycles of DEBIRI(using 100-300 μm beads loaded with irinotecan at a total dose 200 mg) followed by 12 cycles of cetuximab that was administered weekly at a first dose of 400 mg/m2 and then 250 mg/m2; good performance status(0-2) and liver functionality(alanine aminotransferase and gamma-glutamyl transferase not exceeding three times the upper limit of normal, total bilirubin not exceeding 2.5 mg/m L). Data were collected retrospectively and included: tumor response(evaluated monthly for 6 mo then every 3 mo), overall response rate(ORR), KRas status, type and intensity of adverse events(G according to the Common Terminology Criteria for Adverse Events v3.0, CTCAE), overall survival(OS) and progression free survival(PFS).RESULTS: Forty consecutive cases of CRC hepatic metastases were included in the study. Median duration of DEBIRITUX was 4.4 mo(range, 4.0-6.5). Sixteen patients(40%) received the planned 2 cycles of DEBIRI and an average of 10 cetuximab cycles. ORR of the whole sample was 50%, in particular 4 patients were complete responders(10%) and 16(40%) partial responders. The most observed side effects(G2) were: post-embolization syndrome(30%), diarrhea(25%), skin rushes(38%) and asthenia(35%). The retrospective evaluation of KRas status(24 wild type, 16 mutated) showed that the group of patients with wild type KRas had ORR significantly higher than mutant KRas. Median follow-up was 29 mo(8-48 range); median PFS was 9.8 mo and OS was 20.4 mo. Future randomized trials are required in this setting to establish a role for DEBIRITUX compared with systemic chemotherapy.CONCLUSION: DEBIRITUX seems to be efficacious after first line chemotherapy for the treatment of unresectable CRC-LM. | Giammaria Fiorentini Camillo Aliberti Donatella Sarti Paolo Coschiera Massimo Tilli Luca Mulazzani Paolo Giordani Francesco Graziano Alfonso Marqués Gonzalez Raul García Marcos Fernando Gómez Mugnoz Maurizio Cantore Stefano Ricci Vincenzo Catalano Andrea Mambrini | 2015 | World Journal of Gastrointestinal Oncology2015，7，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员